Cidara Therapeutics (United States)

Recent papers from Cidara Therapeutics (United States)

1. Abstract 2644: Enhancing safety to unlock efficacy: A novel class of conditionally-activated T cell engagers for solid tumors.Cancer Research · 2026
2. A Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of CD388, a Novel Drug-Fc-Conjugate, for Prevention of Illness due to Influenza A and B in Healthy Unvaccinated ParticipantsOpen Forum Infectious Diseases · 2026
3. Prophylactic Efficacy of CD388, a Novel Drug–Fc Conjugate, in a Human Influenza A/H3N2 Virus Challenge Model: A Randomized, Controlled Phase 2a StudyClinical Infectious Diseases · 2025
4. Absorption, distribution, metabolism, and excretion of an antiviral drug-Fc conjugate CD388 following subcutaneous administration of 14C-CD388 in the ratDrug Metabolism and Disposition · 2025
5. Activity of rezafungin against Candida aurisJournal of Antimicrobial Chemotherapy · 2025
6. Drug tissue concentration and STAT3 modulation as determinants of tofacitinib response in ulcerative colitisJournal of Crohn s and Colitis · 2025
7. Drug–Fc conjugate CD388 targets influenza virus neuraminidase and is broadly protective in miceNature Microbiology · 2025
8. Anti-TNF nonresponse in ulcerative colitis: correcting for mucosal drug exposure reveals distinct cytokine profilesJournal of Crohn s and Colitis · 2025
9. Clinical and mycological outcomes of candidaemia and/or invasive candidiasis by Candida spp. and antifungal susceptibility: pooled analyses of two randomized trials of rezafungin versus caspofunginClinical Microbiology and Infection · 2024
10. The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometricsJournal of Antimicrobial Chemotherapy · 2024
11. Length of hospital and intensive care unit stay in patients with invasive candidiasis and/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trialsCritical Care · 2024
12. Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trialsCritical Care · 2024
13. In Vivo Efficacy of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in a Neutropenic Mouse Bloodstream Infection ModelJournal of Fungi · 2024
14. Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE StudyClinical Infectious Diseases · 2024
15. CTC-177, a novel drug–Fc conjugate, shows promise as an immunoprophylactic agent against multidrug-resistant Gram-negative bacterial infectionsJAC-Antimicrobial Resistance · 2024
16. CD388: A universally protective Drug-Fc Conjugate that targets influenza virus neuraminidase2024
17. Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjectsPharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2024
18. Abstract LB131: CBO421, a novel drug Fc-conjugate, inhibits the enzymatic activity of CD73 and triggers CD73 internalizationCancer Research · 2024
19. Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasisAntimicrobial Agents and Chemotherapy · 2024
20. Abstract 2668: CBO421: A novel drug Fc-conjugate to prevent tumor immune evasion via the CD73/adenosine pathwayCancer Research · 2024